For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative | 1,356 | |||
| Transaction expenses | 3,955 | |||
| Total operating expenses | 5,311 | |||
| Operating loss | -5,311 | |||
| Interest and dividend income | 1,921 | |||
| (loss) income before income tax expense | -3,390 | |||
| Income tax expense | 19 | |||
| Net (loss) income | -3,409 | |||
| Dividends on series c preferred stock | 2,124 | |||
| Net loss available to common shareholders | -5,533 | |||
| Basic EPS | -0.07 | |||
| Diluted EPS | -0.07 | |||
| Basic Average Shares | 74,215,000 | |||
| Diluted Average Shares | 74,215,000 | |||
ENZON PHARMACEUTICALS, INC. (ENZN)
ENZON PHARMACEUTICALS, INC. (ENZN)